An exclusive licensing agreement for the commercialization and further development of the oncology drug cabozantinib has been signed between Exelixis and Ipsen. The French company will have exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan, including the EU’s approved treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Under the agreement, Exelixis will receive a $200 million upfront payment. Other milestones may include the approval in Europe for advanced renal cell carcinoma (RCC) and the filing and approval in Europe for advanced hepatocellular carcinoma (HCC)